Evidence map›Paper›PMID 42343060›Full record

ArticleMolecular neurobiology2026

Epigenetic Dysregulation of the Wnt/β-Catenin Pathway via FTO-m6A in the mPFC Contributes to Autism-Like Behaviors.

Liting Xue, Ningxia Zhang, JiaLu Zhao, Ying Zhang, Jionglu Zhu, Hongen Wei

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Liting XueShanxi Key Laboratory of Neurobehavior and Brain Disease Control, Shanxi Provincial People's Hospital, Taiyuan, 030012, China. xuelt@sxmu.edu.cn.
Ningxia ZhangShanxi Key Laboratory of Neurobehavior and Brain Disease Control, Shanxi Provincial People's Hospital, Taiyuan, 030012, China.
JiaLu ZhaoChina National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Ying ZhangDepartment of Medical Genetics and Developmental Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China.
Jionglu ZhuShanxi Key Laboratory of Neurobehavior and Brain Disease Control, Shanxi Provincial People's Hospital, Taiyuan, 030012, China.
Hongen WeiShanxi Key Laboratory of Neurobehavior and Brain Disease Control, Shanxi Provincial People's Hospital, Taiyuan, 030012, China.

Funding

the Fundamental Research Program of Shanxi Province 202303021222350the Shanxi Key Laboratory of Neurobehavior and Brain Disease Control 202504010931047
6 · The paper itself

Abstract

Post-transcriptional modifications of RNA, particularly m6A methylation, are emerging as critical epigenetic regulators of neurodevelopment and behavior. Although the RNA demethylase, fat mass and obesity-associated (FTO) protein has been implicated in autism spectrum disorder (ASD), the precise mRNA targets and downstream molecular pathways through which it governs behavior remain unclear. Here, we identify a significant upregulation of FTO in the medial prefrontal cortex (mPFC) of BTBR mice, a well-established ASD model. Targeted knockdown of Fto in the mPFC successfully ameliorates core ASD-like behavioral deficits. Mechanistically, m6A methylome analysis reveals Ctnnb1 (encoding β-catenin) as a direct functional substrate of FTO. FTO-mediated m6A demethylation of Ctnnb1 mRNA enhances its expression, driving aberrant hyperactivation of the Wnt/β-catenin signaling pathway. Translating these molecular insights, systemic pharmacological inhibition of the Wnt/β-catenin pathway partially rescues the behavioral phenotypes in BTBR mice. Importantly, in vivo fiber photometry revealed that this pharmacological rescue is accompanied by the restoration of impaired calcium dynamics in mPFC excitatory neurons during novel object recognition. Together, these findings elucidate a novel epitranscriptomic mechanism whereby the mPFC FTO-m6A-Ctnnb1 axis drives ASD-like phenotypes. Furthermore, they provide preclinical evidence that targeting this specific epigenetic and signaling pathway represents a highly viable pharmacological strategy for ASD intervention.

Indexed as

Alpha-Ketoglutarate-Dependent Dioxygenase FTOAutistic DisorderBehavior, AnimalEpigenesis, GeneticPrefrontal CortexRNA MethylationWnt Signaling PathwayAdenosineAnimalsbeta CateninGene Expression ProfilingHumansMaleMiceMice, Inbred C57BLRNA, MessengerAdenosineAlpha-Ketoglutarate-Dependent Dioxygenase FTObeta CateninFTO protein, mouseN-methyladenosineRNA, MessengerAutismEsculetinFTON6-methyladenosineWnt/β-catenin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.